Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease

Departments of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
Surgical Neurology (Impact Factor: 1.67). 06/2008; 71(5):551-8. DOI: 10.1016/j.surneu.2008.03.039
Source: PubMed

ABSTRACT Neurocognitive outcome research of individuals with Parkinson's disease after unilateral pallidotomy is inconsistent. Although some studies reported few cognitive changes, other investigations have more consistently shown both transient and long-term cognitive decline postoperatively.
We report the long-term motor and neurocognitive outcome 5 years post surgery for 18 patients with Parkinson's disease (12 men and 6 woman; all right-handed) who underwent right or left unilateral posteroventral pallidotomy.
Pallidotomy patients revealed long-term motor benefits from the surgery in their "off" state and control of dopa-induced dyskinesias in their "on" state, which is consistent with previous research. We found mild declines in oral and visuomotor information processing speed, verbal recognition memory, and mental status 5 years after surgery, which differs from previous literature regarding the long-term neurocognitive outcome after pallidotomy. Differences between the right and left pallidotomy patients for both motor and cognitive skills were not found.
Although deep brain stimulation is presently the treatment of choice, pallidotomy continues to be performed around the world. Consequently, although unilateral pallidotomy should be considered a treatment option for patients with Parkinson's disease who suffer from severe unilateral disabling motor symptoms or dyskinesias, the long-term neurocognitive outcome should also be considered in treatment decisions.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of Parkinson’s disease (PD) increases with age and is projected to increase in parallel to the rising average age of the population. The disease can have significant health-related, social, and financial implications not only for the patient and the caregiver, but for the health care system as well. While the neuropathology of this neurodegenerative disorder is fairly well understood, its etiology remains a mystery, making it difficult to target therapy. The currently available drugs for treatment provide only symptomatic relief and do not control or prevent disease progression, and as a result patient compliance and satisfaction are low. Several emerging pharmacotherapies for PD are in different stages of clinical development. These therapies include adenosine A2A receptor antagonists, glutamate receptor antagonists, monoamine oxidase inhibitors, anti-apoptotic agents, and antioxidants such as coenzyme Q10, N-acetyl cysteine, and edaravone. Other emerging non-pharmacotherapies include viral vector gene therapy, microRNAs, transglutaminases, RTP801, stem cells and glial derived neurotrophic factor (GDNF). In addition, surgical procedures including deep brain stimulation, pallidotomy, thalamotomy and gamma knife surgery have emerged as alternative interventions for advanced PD patients who have completely utilized standard treatments and still suffer from persistent motor fluctuations. While several of these therapies hold much promise in delaying the onset of the disease and slowing its progression, more pharmacotherapies and surgical interventions need to be investigated in different stages of PD. It is hoped that these emerging therapies and surgical procedures will strengthen our clinical aramamentum for improved treatment of PD.
    Pharmacology [?] Therapeutics 11/2014; DOI:10.1016/j.pharmthera.2014.05.010 · 7.75 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The dorsal pallidal complex is made up of the external and internal segments of the globus pallidus (GPe and GPi respectively). It is part of the main axis of the basal ganglia (BG) that connects the thalamo-cortical networks to the BG input stages (striatum and subthalamic nucleus) and continues directly, and indirectly through the GPe, to the BG output stages (GPi and substantia nigra reticulata). Here we review the unique anatomical and physiological features of the pallidal complex and argue that they support the main computational goal of the BG main axis (actor); namely, a behavioral policy that maximizes future cumulative gains and minimizes costs. The three mono-layer competitive networks of the BG main axis flexibly extract relevant features from the current state of the thalamo-cortical activity to control current (ongoing) and future actions. We hypothesize that the striatal and the subthalamic projections neurons act as mono-stable integrators (class I excitability) and the in-vivo pallidal neurons act as bi-stable resonators (class II excitability). GPe neurons exhibit pausing behavior because their membrane potential lingers in the vicinity of an unstable equilibrium point and bi-stability, and these pauses enable a less-greedy exploratory behavioral policy. Finally, degeneration of midbrain dopaminergic neurons and striatal dopamine depletion (as in Parkinson's disease) lead to augmentation of striatal excitability and competitive dynamics. As a consequence the pallidal network, whose elements tend to synchronize as a result of their bi-stable resonance behavior, shifts from a Poissonian-like non-correlated to synchronous oscillatory discharge mode.
    Neuroscience 09/2011; 198:171-92. DOI:10.1016/j.neuroscience.2011.08.068 · 3.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The surgical lesion of different brain structures has been used as a treatment for Parkinson's disease (PD) for several decades. More recently, the favored therapeutic approach has involved the administration of levodopa and the use of DBS. These two major therapeutic advances have greatly modified both the clinical condition of patients and the history of the disease. With the introduction of L-dopa in 1967, patients could regain mobility, because their akinesia, tremor, and rigidity were greatly improved, with consequent significant improvement in quality of life and increased life expectancy. However, after the so-called "honeymoon" period in which the disease seemed to be controlled, motor fluctuations and L-dopa-induced dyskinesias mitigated the initial enthusiasm. In the 1990s, unilateral pallidotomy and DBS of the globus palllidus internus and STN reduced these motor fluctuations and dyskinesias remarkably, thereby inaugurating a new era in the surgical treatment of PD. Short- and medium-term follow-up studies of patients who underwent surgery have documented sustained, significant motor benefits. However, given the progressive nature of PD and the purely symptomatic effects of pallidotomy and DBS, the long-term clinical evolution of these surgical patients currently seems to be associated with a new PD phenotype, mainly characterized by axial motor problems and cognitive impairment. Here, we analyze the long-term clinical outcomes of surgical PD patients with at least 5-year follow-up, focusing on the long-term motor symptoms that were initially responsive to surgery. © 2012 Movement Disorder Society.
    Movement Disorders 12/2012; 27(14). DOI:10.1002/mds.25214 · 5.63 Impact Factor

Full-text (2 Sources)

Available from
May 26, 2014